Table 2.
Study outcomes
| Study | Median follow-up (mo) | Mean procedure time (min) | En-bloc resection (n) | R0 resection (n) | Curative resection (n) | Bleeding | Perforation | Local recurrence (n) | Metachronous tumors (n) | Additional surgery after ESD (n) | Histopathology (n) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Iacopini et al. (2015)15 | 24 | 75.3 | 8 | 8 | 7 | 1 | 0 | 0 | 0 | 1 | SSA 1, LGD 4, HGD 3, adenocarcinoma 2 |
| Kasuga et al. (2021)16 | 25 | 95 | 10 | 9 | 9 | 3 | 0 | 0 | 2 | 1 | LGD 6, HGD 2, SSP/A 2, adenocarcinoma 1 |
| Kochhar et al. (2018)17 | 6 | NA | 6 | NA | NA | 0 | 0 | 0 | NA | 1 | LGD 3, HGD 2, IND 2 |
| Kinoshita et al. (2019)18 | 21 | 71.1 | 25 | 19 | 14 | 0 | 1 | 0 | 1 | 5 | LGD 19, HGD 7, adenocarcinoma 4, regenerative atypia 2 |
| Lightner et al. (2021)19 | 19 | 41 | 23 | 23 | NA | 0 | 1 | 0 | 0 | 10 | LGD 8, HGD 9, adenocarcinoma 3 |
| Matsumoto et al. (2021)20 | 180 | 55 | 10 | 8 | 8 | 0 | 0 | 0 | 5 | 4 | LGD 9, HGD 3 |
| Manta et al. (2021)21 | 37 | NA | 53 | 51 | 51 | 7 | 3 | 0 | 2 | 2 | LGD 37, HGD 14, IND 1, hyperplastic polyp 1 |
| Matsui et al. (2021)22 | 25 | 155 | 17 | 12 | 12 | 0 | 0 | 0 | 1 | 1 | Adenoma 2, LGD 4, HGD 4, adenocarcinoma 7 |
| Ngamruengphong et al. (2022)23 | 18 | 93 | 43 | 34 | 3 | 4 | 1 | 1 | 11 | 2 | LGD 28, HGD 9, SSA/P 4, adenocarcinoma 4 |
| Nishio et al. (2021)24 | 37 | 67 | 38 | 38 | 38 | 0 | 4 | 0 | 2 | 4 | LGD 17, HGD 13, serrated polyps 9 |
| Suzuki et al. (2017)25 | 33 | 87 | 29 | 23 | NA | 1 | 0 | 1 | 3 | 4 | LGD 19, HGD 7, adenocarcinoma 4, regenerative atypia 2 |
| Yang et al. (2019)26 | 25 | 73.5 | 14 | 12 | NA | 0 | 0 | 2 | 2 | 2 | SSA/P 1, IND 1, LGD 8, HGD 3, adenocarcinoma 2 |
ESD, endoscopic submucosal dissection; SSA, sessile serrated adenoma; LGD, low-grade dysplasia: HGD, high-grade dysplasia; IND, indefinite dysplasia; SSA/P, SSA/polyp; NA, not applicable.